公开(公告)号：US11071793B2

公开(公告)日：2021-07-27

申请号：US15507214

申请日：2015-08-28

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Christopher John Brown ,  Thomas Martin Krülle ,  Daniel Clark-Frew ,  Sarah Hayes

IPC: A61K51/00 ,  A61M36/14 ,  A61K51/04 ,  C07D401/14 ,  C07D403/04 ,  C07D401/04 ,  C07D487/04 ,  C07D513/04 ,  C07D513/14

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US10907197B2

公开(公告)日：2021-02-02

申请号：US15507217

申请日：2015-08-28

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Christopher John Brown ,  Michael Edward Prime ,  Derek Alexander Weddell ,  Daryl Simon Walter ,  Paul Richard Giles ,  Ian James Wigginton ,  Malcolm George Taylor ,  Sébastien René Gabriel Galan ,  Peter David Johnson ,  Thomas Martin Krülle ,  Inaki Morao ,  Daniel Clark-Frew

IPC: C07D253/08 ,  C07D401/04 ,  C07D473/00 ,  C12Q1/6823 ,  A61K51/04

Abstract: Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US10479802B2

公开(公告)日：2019-11-19

申请号：US15507208

申请日：2015-08-28

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Samuel Coe ,  Jonathan Bard ,  Peter David Johnson ,  Michael Edward Prime ,  Christopher John Brown ,  Sébastien René Gabriel Galan ,  Paul Richard Giles ,  Elise Luciennen Paulette Gadouleau ,  Thomas Martin Krülle ,  Daniel Clark-Frew ,  John Wityak ,  Alex Kiselyov ,  Sarah Hayes

IPC: C07D513/04 ,  C07D413/14 ,  C07D471/04 ,  A61K51/04 ,  C07D413/12 ,  C07D263/57 ,  C07D498/04 ,  C07D405/14 ,  C07D413/04

Abstract: Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US20190062321A1

公开(公告)日：2019-02-28

申请号：US16049482

申请日：2018-07-30

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Ignacio Muñoz-Sanjuán ,  Roland W. Bürli ,  Christopher A. Luckhurst ,  Daniel R. Allen ,  Gilles Raphy ,  Perla Breccia ,  Alan F. Haughan ,  Grant Wishart ,  Samantha J. Hughes ,  Rebecca E. Jarvis ,  Huw D. Vater ,  Stephen D. Penrose ,  Michael Wall ,  Andrew J. Stott ,  Elizabeth A. Saville-Stones

IPC: C07D417/04 ,  C07D275/04 ,  C07D231/56 ,  C07C259/08 ,  C07D277/60 ,  C07D231/54 ,  C07D239/74 ,  C07D239/70 ,  C07D403/04 ,  C07D401/04 ,  C07D239/88

CPC classification number: C07D417/04 ,  C07C259/08 ,  C07D231/54 ,  C07D231/56 ,  C07D239/70 ,  C07D239/74 ,  C07D239/88 ,  C07D275/04 ,  C07D277/60 ,  C07D401/04 ,  C07D403/04

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.

公开(公告)号：US20190047977A1

公开(公告)日：2019-02-14

申请号：US15948821

申请日：2018-04-09

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Leticia Toledo-Sherman ,  Michael Prime ,  William Mitchell ,  Naomi Went

IPC: C07D327/06 ,  C07D319/16 ,  C07D311/02 ,  C07D311/04 ,  C07D263/58 ,  C07D235/26 ,  C07D215/06 ,  C07D307/79 ,  C07D211/72 ,  C07D263/38 ,  C07D233/70 ,  C07D319/18 ,  C07D317/62 ,  C07D317/46 ,  C07D317/50

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US20180222838A1

公开(公告)日：2018-08-09

申请号：US15813001

申请日：2017-11-14

Applicant: CHDI Foundation, Inc.

Inventor： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  William Leonard Mitchell ,  Peter Johnson ,  Naomi Went

IPC: C07C62/38 ,  C07H15/20 ,  C07D203/10 ,  C07C69/757 ,  C07D307/80 ,  C07D307/54 ,  C07D305/08 ,  C07D305/06 ,  C07D295/155 ,  C07D207/337 ,  C07D271/07 ,  C07D207/08 ,  C07C235/82 ,  C07D263/58 ,  C07D203/08 ,  C07D257/04 ,  C07C229/48 ,  C07C229/46 ,  C07C229/22 ,  C07C323/62 ,  C07D413/10 ,  C07D413/08 ,  C07C317/44 ,  C07D405/12 ,  C07D405/10 ,  C07D405/08 ,  C07D403/10 ,  C07D235/26 ,  C07D233/64 ,  C07D319/18 ,  C07D317/60 ,  C07D317/46 ,  C07D311/58 ,  C07D215/18 ,  C07D309/10 ,  C07D307/94 ,  C07D307/79 ,  C07D413/12

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US09855267B2

公开(公告)日：2018-01-02

申请号：US15335279

申请日：2016-10-26

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Perla Breccia ,  Christopher A. Luckhurst ,  Roland W. Bürli ,  Andrew J. Stott

IPC: A61K31/505 ,  A61K31/165 ,  A61K31/357 ,  A61K31/4418 ,  A61K31/421 ,  A61K31/426 ,  C07D213/74 ,  C07D311/58 ,  C07D319/18 ,  C07D401/04 ,  C07D237/08 ,  C07D239/26 ,  C07D239/30 ,  C07D239/34 ,  C07D241/12 ,  C07D417/04 ,  C07D263/32 ,  C07D277/30 ,  C07D213/56 ,  C07D213/61 ,  C07D263/56 ,  C07D215/18 ,  C07D277/64 ,  C07D295/155 ,  C07C259/08

CPC classification number: A61K31/505 ,  A61K31/165 ,  A61K31/357 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4418 ,  C07B2200/07 ,  C07C259/08 ,  C07C2601/02 ,  C07D213/56 ,  C07D213/61 ,  C07D213/74 ,  C07D215/18 ,  C07D237/08 ,  C07D239/26 ,  C07D239/30 ,  C07D239/34 ,  C07D241/12 ,  C07D263/32 ,  C07D263/56 ,  C07D277/30 ,  C07D277/64 ,  C07D295/155 ,  C07D311/58 ,  C07D319/18 ,  C07D401/04 ,  C07D417/04

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.

公开(公告)号：US09783488B2

公开(公告)日：2017-10-10

申请号：US14776280

申请日：2014-03-10

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Ignacio Muñoz-Sanjuán ,  Michel Maillard ,  Gilles Raphy ,  Alan F. Haughan ,  Christopher A. Luckhurst ,  Rebecca E. Jarvis ,  Roland W. Bürli ,  Perla Breccia ,  Grant Wishart ,  Samantha J. Hughes ,  Daniel R. Allen ,  Stephen D. Penrose

IPC: A61K31/133 ,  C07C233/60 ,  C07D263/56 ,  C07D215/14 ,  C07D231/12 ,  C07D231/56 ,  C07D333/54 ,  C07D235/08 ,  C07D239/26 ,  C07D471/04 ,  C07D265/36 ,  C07D277/64 ,  C07D295/073 ,  C07D213/54 ,  C07D213/56 ,  C07D307/79 ,  C07C259/08 ,  C07D209/46 ,  C07D213/58 ,  C07D215/06 ,  C07D235/06 ,  C07D263/57 ,  C07D265/30 ,  C07D277/66 ,  C07D307/81 ,  C07D311/96 ,  C07D401/12 ,  C07D413/06

CPC classification number: C07C233/60 ,  C07C259/08 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/18 ,  C07D209/46 ,  C07D213/54 ,  C07D213/56 ,  C07D213/58 ,  C07D215/06 ,  C07D215/14 ,  C07D231/12 ,  C07D231/56 ,  C07D235/06 ,  C07D235/08 ,  C07D239/26 ,  C07D263/56 ,  C07D263/57 ,  C07D265/30 ,  C07D265/36 ,  C07D277/64 ,  C07D277/66 ,  C07D295/073 ,  C07D307/79 ,  C07D307/81 ,  C07D311/96 ,  C07D333/54 ,  C07D401/12 ,  C07D413/06 ,  C07D471/04

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.

公开(公告)号：US20170283439A1

公开(公告)日：2017-10-05

申请号：US15507203

申请日：2015-08-28

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Alex Kiselyov ,  Christopher John Brown ,  Michael Edward Prime ,  Peter David Johnson ,  Daniel CLark-Frew

IPC: C07D519/00 ,  A61K51/04 ,  C07D471/04

CPC classification number: C07D519/00 ,  A61K51/0455 ,  A61K51/0459 ,  C07D471/04

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US20160333001A1

公开(公告)日：2016-11-17

申请号：US15148884

申请日：2016-05-06

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Michel C. Maillard ,  Perla Breccia ,  Alan F. Haughan ,  Rebecca E. Jarvis ,  Christopher A. Luckhurst ,  Elizabeth A. Saville-Stones ,  Andrew J. Stott ,  Amanda Van de Poël ,  Michael Wall ,  Grant Wishart

IPC: C07D413/12 ,  C07D491/107

CPC classification number: C07D413/12 ,  C07D491/107

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.